Galimedix, Inc. | Finanzwire

Basculer en Français

11086	Companies
243510	Keywords
171684	Articles
131186	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 09/22/2026 at 13:05, 6 days 15 hours ago

Galimedix Announces Fall 2026 Conference Participation

Biotechnology Investor Conferences Alzheimer's Research Scientific Presentations Neuroprotective Therapies
PRESS RELEASE

published on 09/22/2026 at 13:00, 6 days 15 hours ago

Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences
Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences in the US and Europe to present novel neuroprotective therapies

Biotechnology Conférences Clinical-stage Galimedix Neuroprotective Therapies
BRIEF

published on 09/21/2026 at 13:05, 7 days 15 hours ago

Galimedix Forms Advisory Board to Guide Alzheimer's Drug Development

Advisory Board Clinical Trials Drug Development Alzheimer's Disease GAL-101
PRESS RELEASE

published on 09/21/2026 at 13:00, 7 days 15 hours ago

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101
Galimedix establishes a Scientific Advisory Board for Alzheimer's disease to guide the development of GAL-101, a novel oral drug candidate, with global experts providing expertise in Phase 2 clinical-stage biotechnology

Scientific Advisory Board Clinical Development Alzheimer's Disease GAL-101 Galimedix
BRIEF

published on 09/11/2026 at 11:35, 17 days 16 hours ago

Galimedix Therapeutics Presents Phase 2 Data at EURETINA Congress

Galimedix Therapeutics Geographic Atrophy EDREAM Study EURETINA Congress Microperimetry
PRESS RELEASE

published on 09/11/2026 at 11:30, 17 days 17 hours ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress on October 1-4, 2026 in Vienna, Austria

Galimedix Therapeutics Phase 2 Geographic Atrophy EDREAM Study EURETINA Congress
BRIEF

published on 03/20/2026 at 08:05, 6 months 8 days ago

Galimedix Unveils Promising Alzheimer’s Prodrug at AD/PD™ 2026

Galimedix Therapeutics Pharmacokinetic Profile Alzheimer’s Treatment Neuroprotective Therapy Oral Prodrug
PRESS RELEASE

published on 03/20/2026 at 08:00, 6 months 8 days ago

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer's candidate at AD/PD™ 2026, demonstrating improved absorption and systemic exposure for patient-friendly dosing

Alzheimer's Disease Galimedix Therapeutics Pharmacokinetic Profile Oral Alzheimer's Candidate AD/PD™ 2026
BRIEF

published on 03/12/2026 at 13:05, 6 months 16 days ago

Galimedix Therapeutics Secures Milestone Payment in Partnership with Théa

Galimedix Therapeutics Théa Open Innovation GAL-101 Trials Ophthalmology Partnership Alzheimer's Advancement
PRESS RELEASE

published on 03/12/2026 at 13:00, 6 months 16 days ago

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation, advancing oral therapy for eye diseases and Alzheimer’s

Phase 1 Trial Alzheimer's Disease Galimedix Therapeutics Milestone Payment Ophthalmology Partnership

1 2 ... 4

Accesswire

Published on 09/29/2026 at 02:30, 2 hours 4 minutes ago

QNX and neueHCT Join Forces to Accelerate Global Intelligent Driving Deployment, Anchored by Major German Automaker Program Win
Published on 09/29/2026 at 00:00, 4 hours 34 minutes ago

Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Published on 09/28/2026 at 23:00, 5 hours 34 minutes ago

CORRECTION FROM SOURCE: Organto Foods Highlights Record First Half Results and Progress on Key Strategic Initiatives
Published on 09/28/2026 at 15:00, 13 hours 34 minutes ago

Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia
Published on 09/28/2026 at 14:45, 13 hours 49 minutes ago

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

View all ACCESSWIRE

EQS Group

Published on 09/28/2026 at 22:14, 6 hours 20 minutes ago

EQS-Adhoc: Extension of the Managing Directors' employment contracts of Carsten Cramer, Lars Ricken and Thomas Treß – Carsten Cramer appointed Chairman of the Management Board
Published on 09/28/2026 at 19:24, 9 hours 9 minutes ago

EQS-Adhoc: Hapag-Lloyd further raises its earnings outlook for the current financial year
Published on 09/28/2026 at 18:00, 10 hours 34 minutes ago

GEVELOT S.A.: Weekly declaration of share buybacks – 09/28/2026 (French only)
Published on 09/28/2026 at 17:53, 10 hours 41 minutes ago

EQS-Adhoc: MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026
Published on 09/28/2026 at 17:49, 10 hours 44 minutes ago

XTPL increased its global project pipeline in H1 2026, building more sales opportunities for subsequent periods

Les Echos

Published on 09/28/2026 at 17:54, 10 hours 39 minutes ago

Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:45, 10 hours 49 minutes ago

Weekly share buyback
Published on 09/28/2026 at 17:35, 10 hours 59 minutes ago

Disclosure of transactions in own shares from September 21 to September 25, 2026
Published on 09/28/2026 at 08:45, 19 hours 49 minutes ago

BAIKOWSKI: 2026 first-half results
Published on 09/28/2026 at 08:02, 20 hours 32 minutes ago

Saint-Gobain signs renewable electricity purchase agreement in the United Kingdom

View all LES ECHOS COMFI WIRE